Thrombotic microangiopathy (TMA) is one of the severe complications after stem cell transplantation (SCT) and is associated with graft-versus-host disease (GVHD) prophylaxis including FK506. In this study, we experimented on rats using FK506 to demonstrate the occurrence of intestinal TMA. FK506 was administrated into Wistar/ ST rats intraperitoneally for 7 days. Rats were examined histopathologically after FK506 injection using light and electron microscopy and immunohistochemistry. FK506 concentrations in whole blood were measured by enzyme immunoassay. In the acute phase, hemorrhagic lesions with multifocal erosions and crypt loss were found in the small intestines of all treated rats. Capillary vessels were dilated, and a few platelet thrombi were found. Electron microscopy demonstrated degenerative swelling of endothelial cells and platelet aggregates adhering to the vessel walls. In the later phase, epithelial regenerative failure, characterized by crypt ghosts, was found in the affected mucosa. Apoptotic epithelial cells were increased in number. The extent of intestinal injury was proportional to the whole blood levels of FK506. The intestinal lesions in rats were consistent with TMA and induced by the injection of FK506 alone. Apoptotic enteropathy was also observed and similar to intestinal GVHD. In this study, we established an intestinal TMA model induced by immunosuppressant (Tacrolimus) only without irradiation.
Introduction
The macrolide drug FK506 is currently used as an immunosuppressant for prophylaxis of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) and rejection after solid organ transplantation. FK506 has been useful in improving the survival of SCT patients. 1, 2 However the use of FK506 has been accompanied by various side effects, and some investigations implicated thrombotic microangiopathy (TMA) as one important cause of morbidity and mortality in SCT patients, which is associated with GVHD prophylaxis including FK506. [3] [4] [5] [6] Nephrotoxicity is the most common adverse effect of FK506 evidenced by animal experiments and renal allografts in humans. [7] [8] [9] [10] [11] [12] It is well known that renal microvascular damage, part of the FK506 nephrotoxicity, predominantly manifests as hemolytic uremic syndrome (HUS). [13] [14] [15] Recent reports disclosed that intestinal type of TMA was a fatal complication after SCT. Immunosuppressants were thought to be one of the causative agents for TMA. 16, 17 As intestines are a common target site of GVHD, and FK506 is often used as an immunosuppressant for prophylaxis of GVHD, it is very important to clarify the relationship between an occurrence of intestinal TMA and FK506.
Because the onset of TMA after SCT has been associated with various etiologies such as infection, GVHD, immunosuppressants including FK506 and cyclosporine A, total body irradiation (TBI), and chemotherapy, 6, 18 it is very difficult to elucidate the pathological findings and the direct cause of intestinal TMA in clinical SCT cases. In this experiment, focusing on the role of FK506 in these pathologies, we demonstrated that intestinal TMA in rats was induced by the injection of FK506 alone, and studied the pathological findings.
Materials and methods

Animals and pharmacological agents
Six-week-old male Wistar/ST rats, purchased from SLC (Hamamatsu, Japan), were used. The animals were maintained under normal conditions according to institute guidelines.
FK506 in solution for injection was purchased from the Fujisawa Pharmaceutical Co. (Osaka, Japan). FK506 was diluted with physiological saline solution.
Experimental design
Sixty-three rats were divided into six groups of nine animals, each according to injection dose of FK506. The control group received physiological saline solution, and each experiment group received FK506 by intraperitoneal injection at respective dose of 0.1, 0.5, 1.0, 3.0, 5.0 and 10.0 mg/kg/day for 7 days. Three randomly chosen rats from each experimented group excluding the 10.0 mg group were killed on days 1, 7, 14 after the week FK506 injections. All rats in the 10.0 mg group died within 3 days after the FK506 injections.
At the time of killing, the rats' blood was collected from the hearts into ethylenediaminetetraacetic acid (EDTA) containing tubes for the measurement of whole-blood FK506 level and the examination of erythrocyte morphology. For histopathologic examination, intestines, kidneys and systemic organs were obtained and immediately fixed with 20% formalin. The tissues obtained were also fixed with glutaraldehyde paraformaldehyde for electron microscopic examination.
This experiment was performed in the Experimental Animal Laboratory of Nagoya University, School of Medicine according to the ethical and environmental guidelines of Nagoya University.
Measurement of FK506 concentration in whole blood FK506 concentrations in whole blood were measured by automated whole-blood microparticle enzyme immunoassay using IMx immunoassay auto analyzer and IMx Tacrolimus II. Dainapak Kit purchased from Dainabbot Co. (Tokyo, Japan), according to the manufacturer's instructions.
Histopathological examination
Formalin-fixed paraffin sections were stained with hematoxylin eosin (HE), periodic acid Schiff (PAS), Masson Trichrome and Azan stain. Immunohistochemical studies were performed on paraffin-embedded tissues by using the streptoavidin-biotin method. Anti-von Willebrand factor (vWF), a-smooth muscle actin (a-SMA), single-strand DNA (ssDNA) (DAKO Co., Glostrup, Denmark) were used as the primary antibodies. Reactions were visualized with 3,3 0 -diaminobenzidine as the chromogen, followed by counter staining with Mayer's hematoxylin.
The tissue blocks for electron microscopic examination were routinely performed and observed using a Hitachi H-7100 transmission electron microscope (Hitachi, Tokyo, Japan).
EDTA-treated blood of rats was smeared on glass slides and stained May-Giemsa stain for the morphological examination of erythrocytes.
Results
FK506 levels in whole blood
FK506 whole blood levels were closely related to the injected dose of FK506 and showed the feature of decrease in the time course after injection as Table 1 .
Histopathologic findings of intestine
At acute phase (on day 1 after FK506 injection). There were hemorrhagic lesions in small intestines of all treated rats. In 0.1, 0.5, 1.0 and 3.0 mg/kg groups, multifocal erosions with small amount of hemorrhage and dilated capillary vessels were found in the affected mucosa. There were no injuries in arterioles of the submucosal layer.
In the 5.0 and 10.0 mg/kg groups, crypt loss and hemorrhage were remarkable compared with the 0.1, 0.5, 1.0 and 3.0 mg/kg groups, and the 10.0 mg/kg groups especially showed severe crypt loss (epithelial denudation) and massive hemorrhage (Figure 1 ). We could also find a few schistocytes in the hemorrhagic lesions. A few Intestinal TMA induced by FK506 in rats M Fujino et al microthrombi stained with vWF and PAS were present in dilated mucosal capillary vessels ( Figure 2 ). The microthrombi were not stained with red by Masson Trichrome and Azan stain. Electron microscopy demonstrated degenerative swelling endothelial cells and platelet aggregation adhering to the wall (Figure 3b ). Submucosal arterioles in the lesions were accompanied by irregular shape, vacuole change and detachment of endothelial cells, and showed necrosis and myxoid degeneration of the vascular wall (Figure 3a) . Immunohistochemically, the necrotic arterioles were diffusely stained with vWF, and the stainability of a-SMA decreased in the wall. The hemorrhagic lesions were related to the site of affected microvessels, and the extent was proportional to the whole blood levels of FK506.
At recovery phase (on days 7 and 14 after FK506 injection). Although minimal acute intestinal injuries remained, the recovery phase was characterized by epithelial regenerative failure such as crypt ghosts in the affected mucosa ( Figure 4) . The mucosa had a number of regenerative immature glands showing goblet cell depletion and mitosis. Altered crypts lined by variably flattened and dysplastic epithelial cells were interspersed among the regenerative glands. There were also some detached degenerative epithelial cells within the crypts. Immunohistochemically, pericryptal fibroblasts surrounding crypts were stained with a-SMA, which demonstrated the outline of crypt ghosts. Apoptotic cells showing expression of ssDNA were found in regenerative immature glands and detached epithelial cells within crypts ( Figure 5 ). The apoptotic epithelial cells were increased in number compared with control group. Most findings of intestinal injury had disappeared by day 14 in all groups.
Histopathologic findings of kidney
Fine cytoplasmic vacuolization of proximal tubular cells was found in all groups receiving FK506 in the acute phase. Microangiopathy characteristic of HUS was evidenced by glomerular capillary narrowing with mesangial proli- 
Morphology of erythrocytes using smear films
Blood smear films showed the usual morphology of erythrocytes without remarkable poikilocytosis including schistocytes in all groups, and revealed only polychromatic cells manifesting a response to hemorrhage at acute phase in the 5.0 mg/kg group.
Discussion
TMA is characterized by obstruction of small arterioles and capillaries with microthrombi consisting of platelet clumps leading to mechanical hemolysis evidenced by fragmented erythrocytes. This pathological process results from vascular endothelial cell damage due to repeated exposure to toxic agents. 15 In this experiment, arterioles in the submucosal layer and capillary vessels in mucosa-manifested thrombonecrotic lesions. The endothelial cell damage was evidenced by irregular shape, swelling, detachment from the wall and extravasative expression of vWF. 19 The myxoid degeneration appeared to result from endothelial cell injury leading to the exudation of blood plasma. Microthrombi consisting of platelets were identified by positive reactivity of vWF and occluded the capillary vessels. A few fragmented erythrocytes were also present in the affected mucosa. The hemorrhagic lesions were related to the size and level of damaged microvessels. These findings indicated that the microvascular damage with platelet thrombi in this experiment were consistent with features of TMA and induced the ischemic injury of intestines.
The onset of TMA after SCT is associated with infections, intensive conditioning chemotherapy, irradiation and GVHD prophylactic agents such as FK506. 6, 18 Although FK506 provided good protection against GVHD, the use of FK506 was followed by a significant increase in the incidence of TMA. [1] [2] [3] [4] [5] [6] It is well known that TMA associated with FK506 manifests as HUS in kidney. [13] [14] [15] The scientific community does not fully recognize intestinal TMA. and there are no reports about the relationship between the occurrence of intestinal TMA and FK506. In this experiment, nephrotoxicity that is the most common adverse effect of FK506 was confirmed by vacuolization in proximal tubules, and renal microvascular injury resembling HUS was evidenced by capillary narrowing. However, the hyaline thrombi were known as a rare finding even in long-term damage. 11 On the other hand, in intestines, the extent of TMA was proportional to the whole blood levels of FK506. TMA was consistently induced in rat intestines by the injection of FK506 alone. The occurrence of TMA was also found to be significantly associated with intensity of GVHD prophylaxis in SCT patients. 3, 6 This observation in humans can be supported by our results showing that intestinal TMA was dependent on the dose of FK506.
Severe TMA is one of the important causes of morbidity, and mortality in SCT patients and a curative therapy has not been established yet. 16, 17 However, the patients suffering from TMA-associated FK506 recovered on withdrawal of FK506.
14 Our experimental animals also recovered from intestinal TMA after withdrawal of FK506 injection. These findings suggested that intestinal TMA does not progress without consecutive exposure to toxic agents and is not an irreversible change. The rescue from fatal progression of TMA is absolutely dependent on early identification of TMA.
GVHD commonly involves the intestine, and mucosal damage and intestinal hemorrhage are often observed in these patients. Intestinal GVHD is diagnosed by recognition of histological change showing erosion, crypt ghosts, mucosal denudation and apoptosis associated with lymphocyte toxic injury. [20] [21] [22] It is noticed that the intestinal lesions in our experiment showed erosion, mucosal denudation, epithelial regenerative failure represented by crypt ghost, and even increased numbers of apoptotic epithelial cells in regenerative immature glands. These histological findings were consistent with the histological criteria of GVHD. Although it is well known that apoptosis is the characteristic finding in intestinal GVHD, apoptosis in gastrointestinal tracts could be found in cases of viral infection, cytotoxic drug treatment, thymoma, radiation, immunodeficiency states and autoimmune enteropathy other than GVHD. 23, 24 The increase of apoptotic epithelial cells in this experiment was probably owing to balancing the high levels of epithelial cell proliferation accompanied by regeneration or disruption of epithelial cells from basement membrane in crypts. 25, 26 It is possible that intestinal TMA occur in human and the pathological findings resemble GVHD. There were recently some reports about intestinal injuries after BMT, which were not properly explained by GVHD alone. The vascular damage and the combination of chemotherapy, radiation and GVHD were suggested to contribute to the intestinal injuries. [27] [28] [29] [30] They might be associated with intestinal TMA induced by GVHD prophylaxis. We must recognize the occurrence of intestinal injuries induced by vasculopathy including TMA in SCT patients.
The toxicity of FK506 is closely associated with plasma concentration. The plasma level of FK506 is changed according to hematocrit, because 98% of FK506 in the blood distributes in erythrocytes. [31] [32] [33] Therefore, anemia presented by most patients with hematological disorders could be an aggravating factor on the toxic effect of FK506.
We have also done the examination by using the chemical-induced anemic rats. However, we observed only a little histological difference between anemia group and usual hematocrit group (data not showed). It is difficult in this rat model to clarify that anemia is the risk factor of intestinal TMA induced by FK506, because of relatively small intraerythrocytic distribution of FK506 in rat. 33 In conclusion, intestinal TMA was induced by intraperitoneal injection of FK506 alone in rats and its severity was dependent on the whole blood levels of FK506. The intestinal TMA at recovery phase showed histological findings resembling GVHD. We must recognize the occurrence of intestinal TMA associated with FK506 in SCT patients. In this experiment, the concept of intestinal TMA was newly confirmed. This model is expected to contribute to study the pathogenesis, prevention and treatment of intestinal injury with vasculopathy in SCT patients.
